Compare Automatic Data Processing Inc (ADP) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Gilead Sciences, Inc. — how do they compare? Automatic Data Processing Inc trades at $269.97 (market cap $107.69B), while Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Automatic Data Processing Inc pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| ADP | GILD | |
|---|---|---|
Market Cap | $107.69B | $168.35B |
Sector | Industrials | Health |
52-Week High | $309.03 | $155.80 |
52-Week Low | $188.79 | $110.56 |
Enterprise Value | $108.73B | $191.42B |
Dividend Yield | 2.51% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
